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Background: We developed a simple and new insulin resistance index derived from a glucose clamp and a meal
tolerance test (MTT) in Japanese patients with type 2 diabetes mellitus.
Methods: Fifteen patients [mean age: 53 years, fasting plasma glucose (FPG) 7.7 mmol/L, HbA1c 7.1% (54 mmol/mol),
body mass index 26.8 kg/m2] underwent a MTT and a glucose clamp. Participants were given a test meal (450 kcal).
Plasma glucose and insulin were measured at 0 (fasting), 30, 60, 120, and 180 min. Serum C-peptide immunoreactivity
(CPR) was measured at 0 (fasting; F-CPR) and 120 min. Homeostasis model assessment of insulin resistance (HOMA-IR)
and insulin sensitivity indices (ISI) were calculated from the MTT results. The glucose infusion rate (GIR) was measured
during hyperinsulinemic–euglycemic glucose clamps.
Results: The mean GIR in all patients was 5.8 mg·kg–1·min–1. The index 20/(F-CPR × FPG) was correlated strongly with
GIR (r = 0.83, P < 0.0005). HOMA-IR (r = −0.74, P < 0.005) and ISI (r = 0.66, P < 0.01) were also correlated with GIR. In 10
patients with mild insulin resistance (GIR 5.0–10.0 mg·kg–1·min–1), 20/(F-CPR × FPG) was very strongly correlated with
GIR (r = 0.90, P < 0.0005), but not with HOMA-IR and ISI (r = −0.49, P = 0.15; r = 0.20, P = 0.56, respectively). In patients
with mild insulin resistance, plasma adiponectin (r = 0.65, P < 0.05), but not BMI or waist circumstance, was correlated
with GIR.
Conclusions: 20/(F-CPR × FPG) is a simple and effective index of insulin resistance, and performs better than HOMA-IR
and ISI in Japanese patients with type 2 diabetes mellitus. Our results suggest that 20/(F-CPR × FPG) is a more effective
index than HOMA-IR in Japanese patients with mild insulin resistance.
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Table 1 Patient characteristics
All patients Patients with mild
insulin resistance
(GIR 5–10 mg kg–1 min–1)
n 15 10
Sex (male/female) 8/7 6/4
Age (years) 53.2 ± 12.7 53.2 ± 15.2
BMI (kg/m2) 26.8 ± 2.7 25.5 ± 2.3
Waist circumstance (cm) 92.8 ± 6.7 91.7 ± 7.9
HbA1c (NGSP) (%) 7.10 ± 0.66 6.90 ± 0.64
(mmol/mol) (55 ± 11) (53 ± 15)
FPG (mmol/L) 7.66 ± 1.29 7.37 ± 1.06
TG (mmol/L) 2.60 ± 2.91 2.86 ± 3.59
HDL-C (mmol/L) 1.40 ± 0.35 1.47 ± 0.56
Adiponectin (μg/mL) 7.86 ± 3.00 8.20 ± 3.64
GIR (mg·kg–1·min–1) 5.80 ± 2.21 6.38 ± 1.50
Data are means ± standard deviation.
GIR glucose infusion rate, BMI body mass index, HbA1c hemoglobin A1c, NGSP
National Glycohemoglobin Standardization Program, FPG fasting plasma
glucose, TG triglyceride, HDL-C high-density lipoprotein cholesterol.
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Type 2 diabetes mellitus is a heterogeneous disease char-
acterized by insulin resistance and defective insulin se-
cretion [1]. The most precise method to assess insulin
resistance is the glucose clamp technique, although this
method is very complicated and expensive [2]. The insu-
lin sensitivity index (ISI, Matsuda–DeFronzo index) is
an index of insulin resistance obtained from the glucose
clamp technique and a 75-g oral glucose tolerance test
(OGTT) [3]. ISI is well correlated with the glucose infu-
sion rate (GIR) derived from the glucose clamp tech-
nique. As OGTTs should be avoided in patients with
severe diabetes because of the risk of hyperglycemia, the
homeostasis model assessment of insulin resistance
(HOMA-IR) index is widely used in clinical practice and
in clinical studies instead [4]. However, the validity of
HOMA-IR may be limited in some patients, particularly
those with a low BMI, decreased β cell function, and
high fasting glucose levels, which are quite common in
lean Korean patients with type 2 diabetes mellitus and
insulin secretory defects, for example [5]. In Japan, ap-
proximately half of all patients with diabetes have a gen-
etic predisposition to the disease, and insulin secretion is
often impaired in lean patients with diabetes mellitus
[6,7]. Additionally, Japanese and Asian patients often
show reduced β cell function, which limits the reliability
of the HOMA-IR in such populations. The quantitative
insulin sensitivity check index (QUICKI) is another accur-
ate index of insulin sensitivity and shows better correla-
tions with the gold-standard euglycemic–hyperinsulinemic
clamp method than other indices, such as the minimal
model index or HOMA. However, the correlation between
QUICKI and glucose clamp data is lower in nonobese sub-
jects without diabetes than in obese subjects or patients
with type 2 diabetes mellitus [8].
Insulin and C-peptide are co-secreted from the pancreas
in an equimolar ratio. This phenomenon has been exploited
to assess prehepatic insulin secretion in humans [9]. Unlike
insulin, C-peptide is not significantly cleared by the liver
and the kinetics of C-peptide are linear at physiological and
supraphysiologic plasma C-peptide concentrations [10].
Therefore, it has been suggested that peripheral C-peptide
levels more closely reflect pancreatic insulin secretion than
do peripheral insulin levels. Moreover, although OGTTs
should not be performed in patients with diabetes, meal tol-
erance tests (MTT) can be performed in these patients.
One study reported that stimulated serum C-peptide levels
during a mixed-meal tolerance test are a gold-standard
measure of endogenous insulin secretion [11]. Based on
these results, we hypothesized that the insulin resistance
index based on C-peptide levels may be superior to an
index based on insulin levels measured during a MTT.
Therefore, we evaluated a new insulin resistance index




Fifteen outpatients with type 2 diabetes mellitus partici-
pated in this study at Tottori University Hospital between
2009 and 2012. Type 2 diabetes mellitus was diagnosed
based on the criteria of the American Diabetes Association
[12]. There were eight males and seven females. The mean
age of the patients was 53.2 years, mean BMI was 26.8 kg/
m2, mean waist circumference was 92.8 cm, mean fasting
plasma glucose was 7.66 mmol/L, mean HbA1c was 7.10%
(54 mmol/mol), mean triglyceride was 2.60 mmol/L, and
mean high-density lipoprotein cholesterol (HDL-C) was
1.40 mmol/L (Table 1). Patients with pancreatic disease, liver
disease, renal failure, or those taking diabetogenic medica-
tions such as corticosteroids were excluded from this study.
Three patients were on diet therapy alone; 12 were using
oral hypoglycemic agents (OHAs), including α-glucosidase
inhibitors (5 patients), dipeptidyl peptidase inhibitors (4)
sulfonylurea (3), glinides (3), and biguanides (2). None of
the patients were using thiazolidinediones or insulin.
This study was approved by the Ethics Committee of
the Faculty of Medicine, Tottori University. Informed
consent was obtained from all of the patients using a
procedure approved by the Ethics Committee.
Meal tolerance test
After fasting for at least 12 h, the participants visited the
clinic in the morning and consumed a test meal pre-
pared by the Japan Diabetes Society (450 kcal/1882 kJ;
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g) [13]. Plasma glucose and insulin were measured at 0
(fasting), 30, 60, 120, and 180 min after the test meal.
Serum C-peptide immunoreactivity (CPR) was measured
at 0 (fasting) and 120 min. Plasma glucose was measured
using the glucose oxidase method. Plasma insulin and
CPR levels were measured using chemiluminescent
immunoassays (CLIA) (human insulin and CPR CLIA kits;
Kyowa Medix, Tokyo, Japan). Plasma insulin was defined
as immunoreactive insulin (IRI). Plasma adiponectin was
measured using an enzyme-linked immunosorbent assay
(ELISA) (human adiponectin ELISA kit; Otsuka, Tokyo,
Japan). HbA1c (JDS: Japan Diabetes Society) was measured
by high-performance liquid chromatography and was
converted to National Glycohemoglobin Standardization
Program (NGSP) values using the following officially certi-
fied equation: NGSP (%) = 1.02 × JDS (%) + 0.25% [14].
The reverse equation is: JDS (%) = 0.980 × NGSP (%) −
0.245%. HbA1c (NGSP) values were also converted to
International Federation of Clinical Chemistry (IFCC)
values (mmol/mol) using the HbA1c converter developed
by Diabetes UK (Macleod House, London, UK).
Euglycemic–hyperinsulinemic clamp
Glucose clamp studies were performed 2 days after the
MTT. The patients were examined in the morning after
an overnight fast. An antecubital vein was cannulated to
administer the infusate. A dorsal vein was cannulated
and kept warm to facilitate venous sampling and provide
arterialized venous blood. Using an artificial endocrine
pancreas (STG 22; Nikkiso, Shizuoka, Japan), the eugly-
cemic–hyperinsulinemic clamp was performed to deter-
mine insulin sensitivity in the peripheral tissues [2]. A
primed constant infusion of insulin (100 mU/m2·min)
and computer-controlled exogenous infusion of glucose
solution were used to achieve steady-state plasma insulin
levels and maintain plasma glucose (PG) levels at 5.2
mmol/L (95 mg/dL). Using an identical insulin infusion
protocol, the steady-state plasma insulin level was previ-
ously reported to be 1200 pmol/L in patients with type 2
diabetes mellitus [15,16]. The steady-state GIR was calcu-
lated at 90–120 min, and the mean GIR during that time
was used as a marker of peripheral insulin sensitivity.
In a previous report, a GIR > 10.0 mg·kg–1·min–1 at an
insulin infusion rate of 100 mU/m2·min was considered
normal [17]. In another study, a GIR < 5.0 mg·kg–1·min–
1 was defined as insulin-resistant [18]. Therefore, in this
study, we defined a GIR of 5.0–10.0 mg·kg–1·min–1 as
mild insulin resistance.
Calculation of insulin resistance indices
HOMA-IR [4] = [fasting plasma glucose (FPG; mmol/L)] ×
[fasting IRI (F-IRI; pmol/L)]/135. The normal range for
HOMA-IR is < 2.5 [19].ISI [3] = 10,000/√{[FPG (mmol/L) × FPI (pmol/L)] ×
[mean glucose × mean insulin during the MTT]}. The
normal range for ISI is > 2.5 [20].
QUICKI [8] = 1/[log(HOMA-IR)] = 1/log{[FPG
(mmol/L)] × [FPI (pmol/L)]/135}.
ΣIRI(0–180) [21] = IRI (0 min) + IRI (30 min) + IRI (60
min) + IRI (120 min) + IRI (180 min).
C-peptide index (CPI) [22] = fasting CPR (F-CPR;
mmol/L)/FPG (mmol/L) × 100
Clamp-like index (CLIX) [23] = serum creatinine (mg/
mL) (×0.85 if male)/{(mean AUC glucose (mg/dl) × mean
AUC C-peptide (ng/mL)} × 6,600 (AUC = area under the
curve). In this study, we used glucose levels at 0, 30, 60,
and 120 min, and CPR levels at 0 and 120 min.
TG/HDL [24] = triglyceride (mmol/L)/high-density
lipoprotein (mmol/L).Statistical analysis
Data are expressed as means ± standard error of the
mean. Correlations between parametric clinical variables
and GIR were determined by Pearson’s correlation ana-
lysis. We also calculated the intraclass correlation coeffi-
cient (ICC) to assess the agreement or consistency
between pairs of indices [25]. We calculated partial cor-
relation coefficients between GIR and 20/(F-CPR × FPG)
with adjustment for the type of hypoglycemic drug/diet
therapy. Values of P < 0.05 were considered significant.
SPSS software version 15.0 (SPSS, Chicago, IL, USA)
was used for all analyses.Results
During the steady state of glucose clamps, the mean GIR
of all patients was 5.80 mg·kg–1·min–1 and the mean in-
sulin level was 1180 ± 282 pmol/L. The mean adiponec-
tin level was 7.86 μg/mL. In the MTT, the mean plasma
glucose levels at 0 and 120 min were 7.66 mmol/L and
10.10 mmol/L, respectively (Table 2). The mean values
for HOMA-IR, ISI, QUICKI, CPI, and CLIX were 2.90,
5.30, 0.30, 8.30, and 8.50, respectively. Although we
tested various indices based on glucose, insulin, and C-
peptide levels, the correlation was strongest between
GIR and 20/(F-CPR × FPG). The mean value for 20/
(F-CPR × FPG) in the study patients was 5.00.
Both F-CPR × FPG (r = −0.81, P < 0.0005) (Table 3)
and 1/(F-CPR × FPG) were correlated with GIR (r =
0.83, P < 0.0005) (Table 3). Based on the regression
equation GIR = 18.7 × 1/(F-CPR × FPG) + 1.16, we pro-
posed the novel index 20/(F-CPR × FPG) to estimate
GIR. The index 20/(F-CPR × FPG) was also strongly cor-
related with GIR (r = 0.83, P < 0.0005) and could esti-
mate GIR (Table 3, Figure 1A). HOMA-IR (r = −0.74, P
< 0.005) (Figure 1B) and ISI (r = 0.66, P < 0.01) were
both correlated with GIR (Figure 1C).
Table 2 Results of the meal tolerance test
Time (min) 0 30 60 120 180
Glucose (mmol/L) 7.66 ± 1.29 8.96 ± 2.34 10.24 ± 3.12 10.10 ± 2.52 8.50 ± 2.47
Insulin (pmol/L) 60.5 ± 39.7 180.0 ± 141.0 220.9 ± 135.5 263.7 ± 147.8 216.3 ± 170.0
CPR (nmol/L) 0.60 ± 0.25 1.60 ± 0.48
Insulin resistance indices calculated from the MTT
Indices HOMA-IR ISI QUICKI CPI 20(F-CPR × FPG)
Value 2.90 ± 1.84 5.30 ± 2.20 0.30 ± 0.02 8.30 ± 4.21 5.00 ± 2.00
Data are means ± standard deviation.
CPR C-peptide immunoreactivity, MTT meal tolerance test, HOMA-IR homeostasis model assessment of insulin resistance, ISI insulin sensitivity index, QUICKI
quantitative insulin sensitivity check index, CPI C-peptide index, F-CPR fasting C-peptide immunoreactivity, FPG fasting plasma glucose.
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GIR 5–10 mg·kg–1·min–1, 20/(F-CPR × FPG) was
strongly correlated with GIR (r = 0.90, P < 0.0005),
whereas HOMA-IR (r = −0.49, P = 0.15) and ISI (r =
0.20, P = 0.56) were not. QUICKI was also strongly cor-
related with GIR in all patients (r = 0.76, P < 0.001), butTable 3 Correlation coefficients between indices of
insulin resistance and glucose infusion rate during the
meal tolerance test
Index All patients GIR 5–10 mg·kg–
1·min–1
(n = 15) (n = 10)
r P r P
HOMA-IR −0.74 < 0.005 −0.49 0.15
ISI 0.66 < 0.01 0.20 0.56
QUICKI 0.76 < 0.001 0.50 0.14
F-IRI −0.66 < 0.01 −0.42 0.22
ΣIRI(0–180 min) −0.59 < 0.05 −0.26 0.54
F-CPR −0.71 < 0.01 −0.75 < 0.05
F-CPR × FPG −0.81 < 0.0005 −0.83 < 0.005
1/(F-CPR × FPG) 0.83 < 0.0005 0.90 < 0.0005
20/(F-CPR × FPG) 0.83 < 0.0005 0.90 <0.0005
CPI −0.52 < 0.05 −0.62 0.06
CLIX 0.40 0.12 0.23 0.52
P-CPR × PPG −0.58 < 0.05 −0.48 0.16
(F-CPR + P-CPR) × (FPG + PPG) −0.68 < 0.005 −0.63 < 0.05
BMI −0.54 < 0.05 −0.27 0.45
Waist circumference −0.11 0.69 −0.13 0.71
TG/HDL −0.11 0.67 −0.32 0.35
Plasma adiponectin 0.52 < 0.05 0.65 < 0.05
Correlation coefficients were determined using Pearson’s product moment
correlation coefficient test.
GIR glucose infusion rate, HOMA-IR homeostasis model assessment of insulin
resistance, ISI insulin sensitivity index, QUICKI quantitative insulin sensitivity
check index, F-IRI fasting immunoreactive insulin, F-CPR fasting C-peptide
immunoreactivity, FPG fasting plasma glucose, CPI C-peptide index, P-CPR 2-h
postprandial C-peptide immunoreactivity, PPG 2-h postprandial plasma
glucose, BMI body mass index, TG triglyceride, HDL-C high-density lipoprotein
cholesterol.not in patients with mild insulin resistance (r = 0.50, P =
0.14). Similarly, CPI was significantly correlated with
GIR in all patients (r = −0.52, P < 0.05), but not in
patients with the mild insulin resistance (r = −0.62, P =
0.06). CLIX was not correlated with GIR in all patients
(r = 0.40, P = 0.12), nor in patients with mild insulin re-
sistance (r = 0.23, P = 0.52). F-CPR (r = −0.71, P < 0.01)
and F-IRI (r = −0.66, P < 0.01) were correlated with GIR
in all patients. Among patients with mild insulin resist-
ance, F-CPR was significantly correlated with GIR (r =
−0.75, P < 0.05), whereas F-IRI was not (r = −0.42, P =
0.22). ΣIRI(0–180) was significantly correlated with GIR in
all patients (r = −0.59, P < 0.05), but not in patients with
mild insulin resistance (r = −0.26, P = 0.54).
In terms of other clinical factors, BMI was significantly
correlated with GIR in all patients (r = −0.54, P < 0.05),
but not in patients with mild insulin resistance (r = −0.27,
P = 0.45; Figure 1D). By contrast, waist circumstance was
not correlated with GIR in all patients (r = −0.11, P =
0.69), nor in patients with mild insulin resistance (r =
−0.13, P = 0.71) (Figure 1E). TG/HDL was not correlated
with GIR in all patients (r = −0.11, P = 0.67), nor in
patients with mild insulin resistance (r = −0.32, P = 0.35).
Plasma adiponectin was correlated with GIR in all patients
(r = 0.52, P < 0.05), and the correlation was greater in
patients with mild insulin resistance (r = 0.65, P < 0.05;
Figure 1F).
We also analyzed calculated the ICC between specific
indices and GIR. The ICC between 20/(F-CPR × FPG)
was 0.828 (P < 0.0001) in all patients and 0.859 (P <
0.0001) in patients with mild insulin resistance. ICC be-
tween GIR and other indices in all patients and patients
with mild insulin resistance were −0.724 (P < 0.001) and
−0.456 (P = 0.079), respectively, for HOMA-IR, and
0.665 (P < 0.005) and 0.198 (P = 0.279), respectively, for
ISI.
Next, we determined partial correlation coefficients
between 20/(F-CPR × FPG) and GIR after adjusting for
the use of hypoglycemic drugs/diet therapy. The correl-
ation between 20/(F-CPR × FPG) and GIR remained sig-






























































































































































Figure 1 Correlation between insulin resistance indices and GIR. Correlations between GIR and 20/(F-CPR × FPG) (A), HOMA-IR (B), ISI (C),
BMI (D), waist circumstance (E), and adiponectin (F) were calculated by simple regression analysis. Black circles = patients with GIR 5–10 (mg·kg–
1·min–1); white circles = patients with GIR < 5 or > 10 mg·kg–1·min–1.
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Table 4 Partial correlation coefficients between





All patients GIR 5–10 mg·kg–1·min–1
(n = 15) (n = 10)
Partial r P Partial r P
All drugs 0.854 < 0.0001 0.917 < 0.0001
Biganide 0.830 < 0.0001 0.902 < 0.0001
Sulfonylurea 0.839 < 0.0001 0.949 < 0.0001
DPP4 inhibitor 0.834 < 0.0001 0.896 < 0.0001
Glinide 0.833 < 0.0001 0.886 < 0.0001
α-GI 0.793 0.001 0.889 < 0.0001
Diet therapy alone 0.854 < 0.0001 0.917 < 0.0001
Correlations between 20/(F-CPR × FPG) and GIR were adjusted for all drugs or
for individual drugs.
DPP4 dipeptidyl peptidase 4, GI glucosidase inhibitor.
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CPR) × 2-h postprandial plasma glucose (PPG) (P-CPR
× PPG). P-CPR × PPG was significantly correlated with
GIR in all patient (r = −0.58, P < 0.05) and showed a
tendency to be correlated with GIR in patients with mild
insulin resistance (r = −0.48, P = 0.16). Another index,
(F-CPR + P-CPR) × (FPG + PPG) was significantly
correlated with GIR in all patients (r = −0.68 P < 0.005)
and in patients with mild insulin resistance (r = −0.63,
P < 0.05).
There were four patients with insulin resistance, which
was defined as GIR <5 mg·kg–1·min–1. All four patients
had HOMA-IR > 2.5, the cutoff for insulin resistance,
but only two patients had ISI < 2.5, another definition of
insulin resistance. Of 10 patients with mild insulin resist-
ance (GIR 5–10 mg·kg–1·min–1), only three had HOMA-
IR > 2.5 and none had ISI <2.5.
Discussion
This study revealed that the index 20/(F-CPR × FPG)
was more strongly correlated with GIR than were
HOMA-IR, QUICKI, ISI, and CPI. Of note, 20/(F-CPR ×
FPG) was also correlated with GIR in patients with mild
insulin resistance, unlike HOMA-IR, QUICKI, and ISI.
HOMA-IR is simple, and the most commonly used
index of insulin resistance. However, HOMA-IR is of
limited use in subjects with a lower BMI, decreased β
cell function, and high FPG levels [5]. As Japanese and
Asian populations often show reduced β cell function,
HOMA-IR is unsuitable in these populations [6,7]. In
our study, HOMA-IR was not correlated with GIR in
patients with mild insulin resistance. QUICKI was also
reported to show weaker correlations with GIR recorded
during glucose clamp in nonobese subjects than in obese
subjects [8], with similar results in our study. Using the
hyperglycemic clamp technique to study glucosetolerance in normotensive Americans, Chiu et al.
reported that Caucasians were more insulin sensitive
than Asian-Americans, and that their β cells compen-
sated for the prevailing insulin sensitivity [26].
Asian-Americans appear to have an ethnic propensity
to insulin resistance that is not explained by obesity. For
example, single nucleotide polymorphisms in the adipo-
nectin gene in Japanese subjects are associated with
insulin resistance and type 2 diabetes mellitus, and may
be mediated by changes in the expression and plasma
concentrations of adiponectin [27]. Matsuhisa et al.
reported that a modified version of HOMA-IR, termed
HOMA-AD, was correlated with the results of glucose
clamp studies. HOMA-AD was calculated as (serum in-
sulin × plasma glucose)/serum adiponectin [28]. BMI
and waist circumference were not correlated with GIR,
but plasma adiponectin was correlated with GIR in
patients with mild insulin resistance in our study. There-
fore, we think that adiponectin is an important mediator
of insulin resistance in Asian individuals. In earlier studies,
individuals with HOMA-IR > 2.5 [19] or ISI < 2.5 [20]
were classified as having insulin resistance. Of 10 patients
with mild insulin resistance (GIR 5–10 mg·kg–1·min–1),
only three had HOMA-IR > 2.5 and none had ISI < 2.5.
Therefore, these indices and the currently accepted ranges
are not appropriate for identifying patients with mild insu-
lin resistance. Consequently, we suggest that HOMA-IR
and ISI are not suitable for Japanese and other Asian
populations.
Insulin and C-peptide are co-secreted in an equimolar
ratio by the pancreas. Unlike insulin, C-peptide is not
cleared by the liver, resulting in a longer half-life [9,10].
Accordingly, we think that an index incorporating C-
peptide levels will perform better than an index based
on insulin levels. Indeed, among patients with mild insu-
lin resistance, the index 20/(F-CPR × FPG) was more
strongly correlated with GIR than were HOMA-IR and
ISI. \These results suggest that plasma C-peptide levels
better reflect insulin bioactivity in skeletal muscle, as the
glucose clamp technique mainly reflects insulin resist-
ance in skeletal muscle. 20/(F-CPR × FPG) also showed
stronger correlations with GIR than did CPI, an index of
insulin secretory ability [22]. Therefore, we consider that
20/(F-CPR × FPG) is superior to CPI for evaluating insu-
lin resistance.
As the index (F-CPR + P-CPR) × (FPG + PPG) was
also more effective than ISI in patients with mild insulin
resistance, we think it provides a simple and effective
index of insulin resistance during a MTT. However, as
20/(F-CPR × FPG) requires a single blood sample and
does not require a MTT, we recommend this index for
screening of insulin resistance.
Our study had several limitations, including the small
number of patients and the variable nature of the
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As only 15 patients participated in this study, our results
require confirmation in a larger study. We also think
that the coefficient “20” included in our index requires
further examination to confirm its validity. Indeed, we
are currently conducting a larger study, the results of
which we plan to publish in the future. It is possible that
the different medications used by the subjects modified
the insulin and C-peptide responses in the MTT. More-
over, as ISI and CLIX were originally obtained from an
OGTT, the differences between the test meal and glu-
cose load may also affect insulin levels. By contrast, CPR
levels accurately reflected insulin resistance determined
during a glucose clamp, despite the variability in
hypoglycemic drugs used by our subjects. Such varia-
tions are often experienced in daily clinical work.
Based on an earlier report, we excluded patients with
serum creatinine > 1.3 mg/dl [29]. If we use our index in
patients with renal insufficiency, a corrective may be
needed in the equation, as with CLIX. As C-peptide se-
cretion is generally lower in patients after pancreas
transplantation, our index may not be suitable for
patients who have undergone pancreas transplantation.
Thigh and calf circumferences are correlated with in-
sulin resistance in patients with type 2 diabetes mellitus
[30]. Unfortunately, we did not measure thigh or calf cir-
cumferences, which should be done in future studies.
Despite these limitations, we think that our study and
the new index may aid routine clinical treatment of Japa-
nese and other Asian patients with type 2 diabetes melli-
tus, particularly because 20/(F-CPR × FPG) is very easy
to calculate using a single blood sample.Conclusion
20/ (F-CPR × FPG) is a simple and effective index of in-
sulin resistance compared with HOMA-IR and ISI in
Japanese patients with type 2 diabetes mellitus. In par-
ticular, 20/(F-CPR × FPG) showed a stronger correlation
with GIR than did HOMA-IR in patients with mild insu-
lin resistance. Furthermore, it is possible to predict GIR
by calculating 20/(F-CPR × FPG). As Japanese and other
Asian patients do not generally show hyperinsulinemia,
we think that our index is particularly effective in these
populations.Abbreviations
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